- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Experts Predict Expanding Reach of Deadly Nipah Virus
Advancements in diagnostics, vaccines, and antivirals offer hope, but One Health collaboration is key to managing future outbreaks.
Jan. 28, 2026 at 9:39am
Got story updates? Submit your updates here. ›
The Nipah Virus (NiV), a zoonotic pathogen with a high fatality rate, is expected to expand its geographic footprint due to climate change, deforestation, and increasing human-animal interaction. Experts are racing to develop rapid diagnostics, vaccines, and antiviral therapies, while emphasizing the importance of a collaborative 'One Health' approach involving veterinary, medical, and environmental health professionals.
Why it matters
The Nipah Virus poses a serious global health threat, with the potential to cause devastating outbreaks. Understanding the evolving landscape of NiV and investing in proactive prevention strategies is crucial to safeguarding public health, especially in regions where the virus may emerge for the first time.
The details
Climate change and habitat loss are driving fruit bats, the natural reservoir of NiV, into closer proximity with human populations and livestock, expanding the virus's geographic range. Researchers have modeled potential spread to previously unaffected regions of South Asia and parts of Africa. Early diagnosis is critical, and scientists are developing rapid, point-of-care tests to enable faster response. Several vaccine candidates are in development, including a recombinant glycoprotein-based vaccine from the NIH and mRNA technology. Antiviral therapies targeting the virus's unique replication mechanisms are also being explored. Ultimately, a 'One Health' approach involving enhanced surveillance, improved biosecurity, and public education is seen as key to managing future NiV outbreaks.
- A 2023 study published in Nature Communications modeled the potential spread of NiV based on bat distribution and climate scenarios.
- The most advanced NiV vaccine candidate, developed by the NIH, is currently in Phase 1 clinical trials.
The players
National Institutes of Health (NIH)
The NIH is developing the most advanced NiV vaccine candidate, a recombinant glycoprotein-based vaccine that has shown promising results in Phase 1 clinical trials.
University of California, Davis
Researchers at UC Davis are investigating a class of drugs called N-glycosidase inhibitors, which appear to disrupt the Nipah virus's ability to evade the immune system.
University of Singapore
A team at the University of Singapore has announced a promising prototype for a rapid, point-of-care diagnostic test that can detect NiV RNA in under an hour with high accuracy.
What’s next
The most advanced NiV vaccine candidate will need to undergo large-scale efficacy trials before it can be approved for widespread use.
The takeaway
Addressing the threat of Nipah Virus requires a comprehensive, collaborative approach that combines advancements in diagnostics, vaccines, and antiviral therapies with a 'One Health' strategy that bridges human, animal, and environmental health domains.
